Cargando…

Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World

Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cari, Luigi, Naghavi Alhosseini, Mahdieh, Mencacci, Antonella, Migliorati, Graziella, Nocentini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144021/
https://www.ncbi.nlm.nih.gov/pubmed/37112792
http://dx.doi.org/10.3390/vaccines11040879
_version_ 1785034002989580288
author Cari, Luigi
Naghavi Alhosseini, Mahdieh
Mencacci, Antonella
Migliorati, Graziella
Nocentini, Giuseppe
author_facet Cari, Luigi
Naghavi Alhosseini, Mahdieh
Mencacci, Antonella
Migliorati, Graziella
Nocentini, Giuseppe
author_sort Cari, Luigi
collection PubMed
description Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of each vaccine, and the expression of the S-protein was evaluated using flow cytometry and ELISA. Vaccines were obtained from three vaccination centers in Perugia (Italy) that provided us with residual vaccines present in vials after administration. Interestingly, the S-protein was detected not only on the cell membrane but also in the supernatant. The expression was dose-dependent only in Spikevax-treated cells. Furthermore, the S-protein expression levels in both cells and supernatant were much higher in Spikewax-than in Comirnaty-treated cells. Differences in S-protein expression levels following vaccine treatment may be attributed to variations in the efficacy of lipid nanoparticles, differences in mRNA translation rates and/or loss of some lipid nanoparticles’ properties and mRNA integrity during transport, storage, or dilution, and may contribute to explaining the slight differences in the efficacy and safety observed between the Comirnaty and Spikevax vaccines.
format Online
Article
Text
id pubmed-10144021
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101440212023-04-29 Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World Cari, Luigi Naghavi Alhosseini, Mahdieh Mencacci, Antonella Migliorati, Graziella Nocentini, Giuseppe Vaccines (Basel) Brief Report Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of each vaccine, and the expression of the S-protein was evaluated using flow cytometry and ELISA. Vaccines were obtained from three vaccination centers in Perugia (Italy) that provided us with residual vaccines present in vials after administration. Interestingly, the S-protein was detected not only on the cell membrane but also in the supernatant. The expression was dose-dependent only in Spikevax-treated cells. Furthermore, the S-protein expression levels in both cells and supernatant were much higher in Spikewax-than in Comirnaty-treated cells. Differences in S-protein expression levels following vaccine treatment may be attributed to variations in the efficacy of lipid nanoparticles, differences in mRNA translation rates and/or loss of some lipid nanoparticles’ properties and mRNA integrity during transport, storage, or dilution, and may contribute to explaining the slight differences in the efficacy and safety observed between the Comirnaty and Spikevax vaccines. MDPI 2023-04-21 /pmc/articles/PMC10144021/ /pubmed/37112792 http://dx.doi.org/10.3390/vaccines11040879 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Cari, Luigi
Naghavi Alhosseini, Mahdieh
Mencacci, Antonella
Migliorati, Graziella
Nocentini, Giuseppe
Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title_full Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title_fullStr Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title_full_unstemmed Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title_short Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
title_sort differences in the expression levels of sars-cov-2 spike protein in cells treated with mrna-based covid-19 vaccines: a study on vaccines from the real world
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144021/
https://www.ncbi.nlm.nih.gov/pubmed/37112792
http://dx.doi.org/10.3390/vaccines11040879
work_keys_str_mv AT cariluigi differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld
AT naghavialhosseinimahdieh differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld
AT mencacciantonella differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld
AT miglioratigraziella differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld
AT nocentinigiuseppe differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld